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Gastroretentive floating microparticles were developed and evaluated for the controlled metronidazole 
delivery for treatment of gastric disease. Floating microparticles, varying in proportions of chitosan and 
hydroxypropyl methylcellulose or ethylcellulose, were obtained by spray drying. Floating microparticles 
were characterized by physicochemical and in vitro studies, according to their floating ability and drug 
delivery. Microparticles presented mean diameter from 1.05 to 2.20 µm. The infrared spectroscopy 
confirmed the drug encapsulation and showed no chemical linkage between microparticles components. 
X-ray diffraction showed changes in the drug`s solid state, from crystalline to amorphous, indicating partial 
drug encapsulation, due to the presence of some crystalline peaks of metronidazole in microparticles. 
All microparticles floated immediately in contact of simulated gastric fluid and both floating and drug 
release profiles were dependent of microparticles composition. Microparticles samples constituted by 
chitosan and hydroxypropyl methylcellulose revealed the best relationship between floating duration 
and drug release, remaining floating during the occurrence of the drug release, ideal condition for the 
floating gastroretentive systems. 
Uniterms: Floating microparticle. Chitosan. Ethylcellulose. Hydroxypropyl methylcellulose. Controlled 
drug delivery.
INTRODUCTION
Gastroretentive systems have received significant 
interest in the past few decades, because they are able to 
sustain the drug release and to prolong the presence of the 
dosage form within the gastrointestinal tract until all the 
drug is completely released (Prajapati, Patel, Patel, 2008; 
Rapolu et al., 2012). Besides being able to continually and 
sustainably deliver drugs to the small intestinal absorption 
window, the improvements provided from gastroretentive 
systems include achieving a greater and prolonged 
therapeutic effect and thus reducing the frequency of 
administration periods, and providing a more effective 
treatment of local stomach disorders (Chen et al., 2010). 
Thereby, various approaches, such as floating, bioadhesive 
and swelling and expanding systems have been developed 
to increase the gastric retention time of dosage forms 
(Rajab et al., 2014; Ferrari et al., 2014; Lemieux, Gosselin, 
Mateescu, 2015; Priyadarshini et al., 2016).
A floating drug delivery system is of particular 
interest for drugs, which have a specific stomach action. 
Metronidazole (MT; 2-methyl-5-nitroimidazole-1-ethanol; 
Figure 1) is a drug used for the treatment and prevention 
of anaerobic microorganism and protozoa infections. MT 
is an active adjunct in treatment of Helicobacter pylori 
(Prasanthi et al., 2011; Emara et al., 2014). It is classified 
as Class I by Biopharmaceutical Classification System, 
has pH independent activity, and it is mainly absorbed 
in the stomach (Krishnaiah et al., 2003; Abou Youssef et 
al., 2015).
H. pylori is a gram-negative bacterium that causes 
infection of the upper gastrointestinal tract (Guimarães, 
FIGURE 1 - Chemical structure of metronidazole.
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Corvelo, Barile, 2008). This infection induces a persistent 
inflammation of the gastric mucosa with different types 
of lesions, such as chronic gastritis, peptic ulcer and 
gastric cancer. The determinants of these outcomes are the 
intensity and distribution of inflammation in the gastric 
mucosa and the gastritis induced by H. pylori is one of the 
most common infections in humans, affecting over 50% 
of the world population, reaching up to 90 % of infected 
individuals in developing countries (Malfertheiner et al., 
2012; Garcia et al., 2014; Payão, Rasmussen, 2016).
Microparticles in oral multiparticulate drug delivery 
system tend to be dispersed in regions of the gastrointestinal 
tract ensuring a more reliable and reproducible release 
profile and more uniform drug absorption (Asghar, 
Chandran 2006). Floating microparticles for the treatment 
of H. pylori allow the buoyancy of dosage form in the 
gastric fluid providing adequate prolongation of drug 
release near to the ecological niche of the bacterium (Abou 
Youssef et al., 2015).
Floating dosage forms may be classified into 
effervescent and non-effervescent systems (Bardonnet 
et al., 2006; Barrocas et al., 2007). The effervescent 
floating devices are constituted by a matrix of expandable 
polymers, polysaccharides or hydrophobic polymers 
associated with gas generating compounds such as sodium 
bicarbonate. When these systems reach the stomach, 
carbon dioxide is released, due to the acidity of gastric 
contents, and then trapped within the device, causing 
them to float. Non-effervescent systems are constituted 
by hydrocolloids which swell in the acid fluid causing the 
reduction in specific density, thus allowing the movement 
towards the top of the liquid, resulting in the fluctuation 
without the gas generator compound device (Barrocas et 
al., 2007; Ferrari et al., 2014).
The aim of this study was to develop effervescent 
floating microparticles using polymers with different 
properties, such as chitosan (CS; swellable polysaccharide), 
hydroxypropyl methylcellulose (HPMC; expandable 
polymer) and ethylcellulose (EC; water-insoluble polymer) 
for gastric retention of MT for H. pylori treatment; and to 
evaluate their physicochemical characteristics, the in 
vitro drug release and floating properties in the simulated 
gastric medium. 
MATERIAL AND METHODS
Material
Chitosan ( low molecular  weight ;  75-85% 
deacetylated) was purchase from Sigma Aldrich (São 
Paulo, Brazil). Metronidazole was purchase from Audaz 
(São Paulo, Brazil). Ethylcellulose (EthocelTM) and 
hydroxypropyl methylcellulose (MethocelTM K4M) were a 
gift from Colorcon (São Paulo, Brazil). Sodium bicarbonate 
was purchase from Synth (São Paulo, Brazil). All other 
reagents and solvents were of analytical grade.
Preparation of floating microparticles
Floating systems were prepared using two different 
methods according to the polymers solubility. Aqueous 
dispersion formulations were prepared to obtain floating 
microparticles with HPMC, a hydrophilic polymer. 
Emulsion formulations were prepared to obtain floating 
microparticles with EC, a water-insoluble polymer. CS 
was used in both types of formulations.
To both methods, the drug (MT) and CS were 
dissolved in acetic acid solution (0.1 N) and the sodium 
bicarbonate (gas generator) was dissolved in purified 
water. The composition of samples was described in 
Table I. Aiming to evaluate the floating ability and 
control of the MT release, the proportions between 
TABLE I - Floating systems composition
Formulation
Composition (g)
MT Sodium bicarbonate HPMC EC CS
Control HPMC:CS - 0.50 1.25  - 1.25
Control EC:CS - 0.50 - 1.25 1.25
HPMC:CS 1:1 1.00 0.50 1.25 - 1.25
HPMC:CS 1:3 1.00 0.50 0.85 - 1.65
HPMC:CS 3:1 1.00 0.50 1.65 - 0.85
EC:CS 1:1 1.00 0.50 - 1.25 1.25
EC:CS 1:3 1.00 0.50 - 0.85 1.65
EC:CS 3:1 1.00 0.50 - 1.65 0.85
MT: metronidazole; HPMC: hydroxypropyl methylcellulose; EC: Ethylcellulose; CS: chitosan.
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HPMC and CS, and between EC and CS, were varied in 
1:1, 1:3 and 3:1. 
Aqueous dispersion formulations were obtained 
varying the proportion of HPMC and CS, keeping the 
drug and the sodium bicarbonate content equal in all 
the samples. Formulations were prepared by mixing all 
components under magnetic stirring during 30 minutes. 
To prepare the emulsion formulations, two phases were 
prepared, an aqueous phase composed by CS, MT (both 
previously dissolved in acid solution), polyvinyl alcohol 
(PVA) at 1.0% (w/v) and sodium bicarbonate, and an 
organic phase composed by EC dispersed in acetone. The 
two phases were also mixed under magnetic stirring during 
30 minutes. The proportions of EC and CS varied. The 
solid content of all samples was 1.0% (4.0 g), and the total 
volume prepared was 400 mL, except control formulations 
(without drug) which were prepared with 3.0 g of solid 
content in 300 mL.
Aqueous dispersion formulations and emulsion 
formulations were taken to spray dryer (mini, mod MSD 
1.0, LABMAQ), under magnetic stirring to obtain the 
microparticles. The conditions of the process were inlet 
temperature of 100 °C for aqueous dispersion and 80 °C 
for emulsion formulations and the sample flow was 0.25 
L.h-1 for both systems.
Physicochemical characterization of floating 
microparticles
Particle Size Analysis
The average microparticles diameter was measured 
by dynamic light scattering method using ZetaSizer® 
equipment (Zetasizer Nanoseries, Malvern Instruments, 
United Kingdom). Microparticles were dispersed into 
water at a dilution of 1:500 and the homogeneous 
suspension could determine the average diameter of the 
microparticles and the size distribution (Hao et al., 2014).
Scanning electron microscopy (SEM)
SEM was performed using the SSX–550 Superscan 
(Shimadzu). Samples were brought to the vacuum oven TE 
395 (Tecnal) and fixed in a metallic form and coating with 
gold in the IC-50 equipment Ion Coater (Shimadzu). The 
micrographs were obtained using accelerating voltages of 
15 kV in several magnifications. 
Fourier Transform Infrared Spectrometry (FTIR)
The FTIR spectra were performed using an IR 
Prestige-21 (Shimadzu). In order to collect the spectra, 
a small amount of microparticles or pure constituents 
was mixed with KBr (Merck IR spectroscopy grade) 
and compressed to obtain tablets. The FTIR spectra, in 
absorbance mode, were obtained in the spectral region of 
400-4000 cm-1 using a resolution of 2 cm-1.
X-Ray Diffraction (XRD)
The analyses were performed on an X-ray 
diffractometer (Shimadzu XRD-6000). Monochromatized 
CuKα radiation (λ=0.154 nm) was used as the X-ray source 
operating at 40 kV. The current flow in the tube was at 40 
mA and the spectrum was recorded in the range of 3° to 
60° 2θ at a scan rate of 2° 2θ.min-1 to check the crystal 
pattern of the pure drug and microparticles, as well as the 
other constituents of the formulations.
Drug loading 
It was performed by pulverization to break 
microparticles and 100 mg of powder were weighted, 
corresponding to 25 mg of MT, and added in 50 mL 
flask with HCl 0.1 mol.L-1. The mixture was stirred for 
60 minutes on a magnetic stirrer. The obtained samples 
were filtered through cellulose acetate membrane (0.45 
μm) and analyzed by UV-Vis spectrophotometer at 277 
nm (Oh, Heng, Chan, 2015). The assay was realized in 
sextuplicate. The related concentrations were calculated 
using calibration profiles based on absorbance versus 
concentration curves previously designed and standardized 
(range concentration of 0.625 to 25.0 µg.mL-1; y = 0.0369x 
+ 0.0066; r2 = 0.9998).
In vitro characterization of the floating 
microparticles
Floating ability 
The floating ability of microparticles was evaluated 
according an adapted method described by Ferrari et al. 
(2014). 50 mg of microparticles were added in 200 mL 
of simulated gastric fluid (HCl 0.1 mol.L-1, pH 1.2) at 
approximately 40 °C at a bath of water with periodical 
stirring at 50 rpm. The lag time and the total floating time 
were visually analyzed.
Drug release 
The dissolution studies were performed using a 
Dissolution Station (Nova Ética® model 299-6A TTS) 
based on United States Pharmacopoeia (2007) Apparatus 
II (paddle method). The acceptor fluid was maintained 
at 37 ± 0.5 °C with the rotation speed set at 50 rpm. The 
release medium was 400 mL of simulated gastric fluid (pH 
1.2) for 4 hours. Test was performed in triplicate.
At appropriate time intervals (15, 30, 45, 60, 90, 
120, 150, 180 and 240 min), 10 mL of the samples were 
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withdrawn and filtered through cellulose acetate membrane 
(0.45 μm). The dissolution medium was replaced with 
the same volume maintaining the sink conditions. The 
filtrate was analyzed by UV spectrophotometer at 277 
nm. The concentrations were calculated using calibration 
profiles based on absorbance versus concentration curves 
previously designed and standardized (range concentration 
of 0.625 to 25.0 µg.mL-1; y = 0.0369x + 0.0066; r2=0.9998). 
The corresponding drug release profiles were represented 
by plots of the cumulative temporal percent amount of 
drug released (calculated from the total amount of MT 
contained in each sample).
Difference (f1) and Similarity (f2) Factors 
Difference factor (f1) is a measurement of the relative 
error between the two dissolution curves and Similarity 
factor (f2) measure the closeness between the two 
dissolution profiles. The factors were calculated according 
to the equations given below:
  Eq. 01
 Eq. 02
where, n is the number of time points, Rj and Tj are the 
dissolution values of the reference product and the test 
product, respectively, at each time point j. In order to 
consider the dissolution profiles similar, f1 values should 
be between 0 and 15, and f2 values higher than 50 (50-100), 
showing the similarity of the dissolution profiles (Costa, 
Lobo, 2001).
Statistical analysis
The statistical analyses were realized by Student’s 
t-test (independent samples) with p<0.05 as the minimal 
level of significance (Martinac et al., 2005). Data were 
analyzed in Microsoft Office Excel 2007. 
RESULTS AND DISCUSSION
Microparticles were obtained by spray drying 
process. All samples presented a slightly yellow color. 
The yield of formulations was similar between samples 
prepared by the same method (or same polymer). Samples 
prepared with HPMC showed 64.71 (± 10.85)% of yield, 
while samples with EC showed 47.28 (±4.98)%. These 
low percentages of yield are due to the equipment, which 
has a larger drying chamber and a cyclone chamber in 
which microparticles remain adhered. The method used 
to prepare the formulations also was responsible for the 
reduction of the percentage of yield, showing lower results 
in emulsion formulations. 
Physicochemical characterization of floating 
microparticles
The results of the mean diameter of the microparticles 
(Table II) show that all samples presented average particles 
size ranging from 1.05 to 2.20 µm. Formulations prepared 
with HPMC and CS presented similar size (p>0.05). The 
particle size of EC and CS formulations was statistically 
different comparing formulations 1:1 and 1:3 (p=0.006), 
indicating that the larger amount of CS contributed to the 
larger size of microparticles.
Polydispersity index is an index ranging from zero, 
when all microparticles of the dispersion presenting 
TABLE II - Results of microparticles characterization
Formulation Average particle size (µm)
Polidispersity 
index
Zeta Potential 
(mV)
Entrapment efficiency 
(%)
Control HPMC:CS 1.43 (± 0.76) 1.000 (± 0.000) 12.45 (± 2.40) -
Control EC:CS 2.04 (± 0.81) 1.000 (± 0.000) 7.21 (± 3.02) -
HPMC:CS 1:1 1.49 (± 0.54) 1.000 (± 0.000) -2.68 (± 2.87) 31.69 (± 0.73)
HPMC:CS 1:3 1.48 (± 0.70) 1.000 (± 0.000) -6.25 (± 2.94) 42.67 (± 1.84)
HPMC:CS 3:1 1.05 (± 0.31) 0.873 (± 0.219) -4.00 (± 2.42) 26.58 (± 0.72)
EC:CS 1:1 1.09 (± 0.49) 1.000 (± 0.000) -3.71 (± 1.96) 44.64 (± 1.74)
EC:CS 1:3 2.20 (± 0.32) 0.663 (± 0.298) -7.66 (± 2.41) 36.91 (± 2.21)
EC:CS 3:1 2.06 (± 0.63) 0.883 (± 0.101) -5.85 (± 3.53) 66.91 (± 2.01)
MT: metronidazole; HPMC: hydroxypropyl methylcellulose; EC: Ethylcellulose; CS: chitosan.
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relatively the same size, and 1.0, when the average 
particle diameter is heterogeneous (Oliveira et al., 2013). 
Microparticles composed by HPMC and CS presented 
index of 1.0 or near of it, indicating low homogeneity 
of the particle size. EC and CS samples presented index 
ranging from 0.663 to 1.0. The particle size could be 
related to the method of preparation, in which samples 
obtained by emulsion were more homogeneous than 
microparticles prepared by aqueous dispersion. 
Zeta potential is a measure that indicates the 
electrical potential that arises when microparticles acquire 
electric charge on its surface in contact with a liquid. 
This electric potential is influenced by changes in the 
particle interface with the dispersing medium, due to the 
dissociation of functional surface groups or the adsorption 
of ionic species present in the aqueous dispersion 
(Schaffazick, Guterres, 2003). The cellulose derivatives 
polymers, HPMC and EC, are non ionic materials and the 
CS is a positive polysaccharide due to the amino groups, 
which acquire electrical charge. The drug, MT, contains 
a nitro group (NO2; Figure 1) presenting negative charge 
in aqueous solution. Results of microparticles showed 
negative charge, which may be related to the presence 
of the drug in the microparticles surface, indicating 
that the drug was not entirely encapsulated. This partial 
encapsulation could be due to a high quantity of drug 
added in formulations, in which the proportion of drug 
and polymers was 1:2.5. These proportions aimed to 
encapsulate a high amount of drug; however, the potential 
zeta analysis, as the entrapment efficiency study showed 
that the drug was not totally encapsulated by polymers 
(Table II). 
The SEM photomicrographs of microparticles, with 
magnification of 2500 x, show the morphology and the 
surface of samples (Figure 2). 
The photomicrographs of the HPMC and CS 
microparticles’ outer surface (Figure 2 A-C) showed that 
the size of particles was not uniform, a typical characteristic 
of particles produced by spray drying. Photomicrographs 
obtained by EC and CS samples (Figure 2 D-F) presented 
more uniform particles, as compared to HPMC and CS 
microparticles, but also showed imperfections on their 
FIGURE 2 - Photomicrographs of microparticles: (A) HPMC:CS 1:1; (B) HPMC:CS 1:3; (C) HPMC:CS 3:1; (D) EC:CS 1:1; 
(E) EC:CS 1:3; (F) EC:CS 3:1 (magnification of 2,500 x). MT: metronidazole; HPMC: hydroxypropyl methylcellulose; EC: 
ethylcellulose; CS: chitosan.
L. Nohemann, M. P. Almeida, P. C. Ferrari
Braz. J. Pharm. Sci. 2017;53(1):e15218Page 6 / 13
surfaces, as well as different sizes. These characteristics 
can be due to the conditions of emulsification process, 
such as rate of stirring, used solvents and type of emulsifier 
(Rinaldi et al., 2009). 
According to Stulzer et al., (2007), the morphology 
of microparticles is probably due to the obtainment 
process, which often produces amorphous compounds, 
due to the rapid drying process, preventing a uniform 
organization of particles. The main variables of the 
drying process are operational, such as inlet and outlet 
air temperature, air flow pattern, temperature distribution 
and humidity and durability time, in addition to structural 
variables, e.g. the atomizer type. All these variables 
can influence in the shaping of microparticles and also 
influence the encapsulation efficiency, as occurred in all 
formulations (Table II).
There are many reasons that cause the low entrapment 
efficiency: (i) duration of spray drying process; (ii) low 
viscosity of the sample, which facilitates the internal 
circulation of droplets, causing coalescence and resulting 
in larger droplets. Furthermore, the increase of internal 
circulation hinders the formation of the membrane during 
the drying process, decreasing the drug retention into 
microparticles, i.e., lower encapsulation efficiency; (iii) 
emulsion stability, which is related to the encapsulation 
efficiency, since a larger amount of unencapsulated drug 
can adhere to the particle’ surface (Barbosa, Borsarelli, 
Mercadante, 2005; Soottitantawat et al., 2003, 2005). 
Besides, other operation variables and characteristics of 
the device itself can contribute to the results found.
Microparticles composed by HPMC and CS showed 
entrapment efficiency varying from 26.6 to 42.7%, and the 
sample containing a higher amount of CS yielded a better 
drug encapsulation. CS is a hydrophilic polymer, soluble 
only in acid solutions and HPMC is also hydrophilic, 
swellable, soluble in water and pH-independent. The 
sample composed by HPMC and CS containing a higher 
amount of CS presented the highest value of encapsulation 
efficiency, indicating more ability of CS to encapsulate 
the MT.
On the other hand, samples prepared with EC and CS 
containing a higher proportion of CS presented the lowest 
encapsulation efficiency (36.9%). EC is a hydrophobic 
polymer, and it`s high amount in the formulation promoted 
more drug retaining (66.9%), while samples composed 
by high amounts of CS, in this case, presented low 
encapsulation of the MT. 
FTIR and XRD studies
FTIR technique allows the identification of organic 
compounds through the functional groups present in the 
molecules. Figure 3 shows the spectra of the formulations 
and their respective constituents.
The absorption bands at 3223 cm-1 (O-H stretching), 
3100 cm-1 (C-H and C=CH stretching), 1535 cm-1 (N-O 
stretching), 1370 cm-1 (NO2 symmetric stretching) and 
1076 cm-1 (C-O stretching, C-H in plane bending) were 
assigned as the fingerprints of MT (Wearley, Anthony, 
1976; Ramukutty, Ramachandran, 2012), and the MT 
spectrum shows their characteristics bands: 3200-3600 
cm-1 attributed to the O-H stretching, 3221-3101 cm-1 
(N-H stretching), 2982-2937 cm-1 (C-H stretching), 1300-
1600 cm-1 attributed to the NO2; 1354-1180 cm-1 (C-O 
stretching), 1428-1368 cm-1 (C-H bending, in plane), 
1340 cm-1 (C-C stretching), 864 cm-1 (C-H out of plane 
bending), 825 cm-1 (C-H out of plane bending and C-N 
stretching), 744 cm-1 ((CH2)2 rocking).
Spectrums were separated in the range of 1600-600 
to better viewing of the peaks. Bands of the MT were 
not presented in the spectrum of control microparticles 
(without drug), signalized by dotted lines. Figure 3B 
shows the peak of MT in 1265.35 cm-1, present in the 
microparticles, except for the control sample, as well as 
the peaks in 864.14, 826.53 and 744.55 cm-1, which did 
not appear in the control sample, confirming the drug 
encapsulation into microparticles. Figure 3D shows the 
MT peaks at 1533.47, 1189.16, 825.56 and 744.55 cm-1, 
only present in the microparticles containing the drug. 
There is a predominance of polymers characteristic 
bands (Table III) in all microparticles samples, and the 
main bands of polymers and the drug were presented in 
microparticles (with less intensity), indicating no chemical 
linkage among them. 
XRD is an important technique to study the crystal 
structure typically found in compounds. Figure 4 shows 
the XRD patterns for the different formulations of 
microparticles. 
MT sample shows high crystalline structure, due 
to the presence of several sharp peaks at 12.02, 13.55, 
17.89, 21.27, 24.54, 27.30, 29.07 and 33.57° 2θ. Polymers 
showed two peaks: CS at 10.18 and 19.72° 2θ, HPMC at 
9.58 and 19.36° 2θ and EC at 7.96 and 20.04° 2θ. These 
polymers present crystalline and amorphous phase when 
pure and in solid state (Suksaeree et al., 2015). 
Microparticles showed low peak intensity and 
baseline shift of the diffractogram was observed, due 
to the presence of polymers when compared to the drug 
pattern, similar to Parida et al. (2016) results. The broad 
and distorted hump in a wide range in the microparticles 
was due to the amorphous phase and the decrease in 
crystallinity of the drug that followed encapsulation in the 
polymeric microparticles (Singh et al., 2015). However, 
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FIGURE 3 - FTIR spectrums of formulations and pure constituents: (A) HPMC and CS samples: wavelength range: 4000 cm-1 
to 500 cm-1; (B) HPMC and CS samples: wavelength range: 1600 cm-1 to 600 cm-1; (C) EC and CS samples: wavelength range: 
4000 cm-1 to 500 cm-1; (D) EC and CS samples: wavelength range: 1600 cm-1 to 600 cm-1. MT: metronidazole; HPMC: hydroxypropyl 
methylcellulose; EC: ethylcellulose; CS: chitosan.
TABLE III - Characteristics bands of used polymers composing the floating microparticles
Bands (cm-1) CS HPMC EC
3400-2400 - O-H stretching O-H stretching
3180-3350 NH2 stretch - -
2900- 2870 - methoxy group (C-CH3) C-H stretching
1735 - C=O stretching (ester group) -
1650-1665 C=O stretching (amine of the 
acetamido)
aromatic ring -
1560-1610 axial deformation  
(NH2 group)
- -
1444-1375 - - CH3; CH2
1300-1000 C-O stretching - C-O-C stretching (cyclic ether)
1276  
1200-1000  
744 
- 
- 
-
ester group  
ether group  
monosubstituted aromatic ring
- 
- 
-
CS: chitosan; HPMC: hydroxypropyl methylcellulose; EC: ethylcellulose.
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some peaks of MT (with lower intensity) were observed 
in microparticles. HPMC and CS microparticles showed 
peaks at 9.10, 12.10, 13.74, 19.90, 25.30, 27.43, 33.19° 
2θ, and EC and CS microparticles at 7.90, 12.16, 13.66, 
19.43, 27.70, 33.24° 2θ, related to the drug and polymers, 
showing that microparticles presented semi-amorphous 
structure, which indicates partial drug encapsulation.
In vitro characterization of the floating 
microparticles
The microparticles floating ability is shown in 
Figure 5. All samples floated immediately when added 
in contact with the simulated gastric fluid. Ten minutes 
after, 10% of microparticles sinked, except the EC:CS 
3:1 formulation (green solid line) which only 50% of 
microparticles remained dispersed. After 30 min of assay, 
samples of HPMC:CS microparticles were hydrated and 
remained floating during 2 hours. 
HPMC and CS microparticles (dotted lines) showed 
the same profile, regardless the proportions between CS 
and HPMC, indicating that the quantity of polymers did 
not influence the flotation time. In contact with simulated 
gastric fluid, the microparticles immediately floated due 
to their low density and maintained due to the medium 
absorption by polymers, which swelled, combined with 
the gas generator substance (sodium bicarbonate) allowing 
the flotation for 2 hours.
 EC and CS microparticles (solid line) showed 
different floating profiles, however all samples immediately 
floated in contact with the medium. EC:CS 1:1 and EC:CS 
3:1 microparticles remained floating during a reduced time 
and after one hour and a half all microparticles stopped 
floating. These formulations contain high proportions of 
EC (equal or more than CS), which is insoluble and not 
swells. Therefore, the swelling of microparticles was 
limited and was not sufficient to maintain their flotation. 
EC:CS 1:3 sample, containing a high quantity of CS, 
floated during 2 hours; due to the gel layer formation 
FIGURE 4 - XRD of microparticles and their constituents: (A) HPMC and CS samples; (B) EC and CS samples. MT: metronidazole; 
CS: chitosan; HPMC: hydroxypropyl methylcellulose; EC: rthylcellulose.
FIGURE 5 - Floating ability of microparticles. CS: chitosan; 
HPMC: hydroxypropyl methylcellulose; EC: rthylcellulose.
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(by CS), which swelled and sustained the gas generated 
by sodium bicarbonate allowing the flotation of the 
microparticles. 
The study of drug release from floating microparticles 
was presented in Figure 6. MT is a water soluble 
drug, belonging to the class I of Biopharmaceutical 
Classification System, i.e. the MT release occurs fast and 
its dissolution is not a limiting step for the absorption. The 
prepared microparticles exhibited prolonged drug release 
in the simulated gastric fluid.
In the first hour, 75% of the drug were released 
from HPMC and CS microparticles, and 95% of MT 
were released in 4 hours. Statistical analysis shows that 
the drug released from HPMC:CS 1:1 and HPMC:CS 
1:3 (p = 0.0122; f1 = 11.82; f2 = 98.07) formulations 
were different. HPMC:CS 1:3 microparticles contains 
more CS and it was responsible for the different drug 
release profile. It was found that CS decreases the rate of 
drug release from microparticles in the beginning of the 
dissolution test in simulated gastric fluid. The obtained 
results in the study conducted by Ritger, Peppas (1987), 
showed that the CS hydration and gel formation takes 
place more readily at acid pH levels (pH 1.2) than at pH 
levels close to neutral, due to its cationic nature (Sahu, 
Verma, Singh, 2012). Higher amounts of CS resulted in 
better control of drug release in the first hour of the test. 
HPMC also contributed in prolonging the drug release due 
to its swelling, associated with the CS swelling. However, 
in formulations containing equal or a higher quantity 
of HPMC (than CS) the drug release were similar (p = 
0.5950; f1 = 5.96; f2 = 70.06).
EC:CS 1:3 sample presented drug release statistically 
different from all other samples (p < 0.05; f1 > 15; f2 < 50), 
showing 60 % of drug released in 4 hours. This sample 
also contains a higher quantity of CS. EC is an insoluble 
polymer that does not swell and reduce the CS swelling 
(CS absorbs the gastric fluid fast, even though it is limited). 
Probably the association of CS and EC induced a stable 
and rigid gel layer, able to control the water uptake into the 
microparticles and this gel layer controlled the MT release 
from microparticles. EC, being hydrophobic, has recently 
been reported to be an excellent backing material, given 
its low water permeability and moderate flexibility, due to 
this insolubility preventing the penetration of water into 
microparticles (Remunan-Lopez et al., 1998; Nunthanid 
et al., 2009).
Formulations containing EC and CS 3:1 were also 
statistically different of all other samples (f1 >15; f2 <50), 
showing fast initial drug delivery followed by a plateau. 
This sample contains a lower quantity of CS and the MT 
was quickly released. It may be attributed to the CS low 
amount, because EC has a low water permeability while 
both CS and the drug are relatively soluble at low pH, 
therefore this formulation had lower gel formation in 
acidic pH, allowing the fast drug release by diffusion 
(Adebisi, Conway, 2014).
MT release from HPMC:CS 1:1 and from EC:CS 1:1 
samples showed similar profile until 90 min of dissolution 
test (t85%; f1=4.32; f2=64.93) ; however it was significantly 
different (p=0.0438) after the first second hour, and a 
greater quantity of drug was released from HPMC and 
CS microparticles than from EC and CS microparticles. 
Samples presented the same proportion between polymers, 
but in the formulation prepared with EC, the CS swelling 
was reduced and the medium intake occurred slowly, 
prolonging the MT delivery.
The development of floating gastroretentive systems 
requires the in vitro assessment of drug release profiles 
as well as the assessment of the floating behavior. Thus, 
a combined evaluation of formulations, which has no 
floating lag time and maintains its floating capabilities 
while releasing the drug was performed (Figure 7). 
After completing the drug release, the delivery systems 
should lose their floating capability, allowing the gastric 
emptying of the microparticles and thus preventing 
possible accumulation of microparticles in the stomach 
after multiple administering. 
According to Amit et al. (2011), the risk of 
microparticles accumulation in the stomach is negligible 
following a single administration; however, potential risk 
of the aggregation and accumulation of drug-depleted 
microparticles in the stomach increases after multiple and 
sequential administrations. Therefore, the microparticles` 
FIGURE 6 - Drug release profile of floating microparticles 
in simulated gastric fluid. MT: metronidazole; CS: chitosan; 
HPMC: hydroxypropyl methylcellulose; EC: ethylcellulose.
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ability to remain floating during the drug release and to 
sink after drug depletion is the ideal characteristic for 
floating microparticles.
Results showed that all microparticles remained 
floating while around 60% of the drug were releasing, 
except EC:CS 3:1 formulation, in which 50% of 
microparticles floated during the release of 40 % of the 
MT. These results reveal that microparticles remain 
floating while most of the drug is being released. 
The developed microparticles exhibited different 
flotation and drug release profiles, according to the 
polymer composition. EC:CS 1:3 microparticles remained 
floating during 100 min, and after 4 hours, only 60 % of 
drug were released while no microparticles remained 
floating. 
HPMC:CS 1:1 and HPMC:CS 3:1 formulations 
showed suitable relation between floating ability and 
MT release, i.e. 90% of microparticles remained floating 
during 60 % of MT release, and only after 80% of drug 
release the microparticles stopped to float. The amount of 
HPMC did not influence the relationship between floating 
and drug release, while the amount of CS caused influence 
(red dotted line; Figure 7), because 10% of microparticles 
remained floating after around 60% of the drug were 
released from sample containing a greater quantity of CS 
than HMPC. 
Microparticles of HPMC:CS formulations can be 
classified as Type I in the model floating behavior category, 
according to Eberle et al. (2016), who refers to the floating 
characteristics of hydrophilic eroding systems, in which 
the floating decrease due to predominant dissolution of 
the microparticles components. Despite 80 % of the drug 
were released in 2 hours, the maintenance of the flotation 
is essential to promote the microparticles retention in 
the stomach and after the drug release the microparticles 
should stop floating to avoid accumulation.
CONCLUSIONS 
Floating microparticles were successfully obtained 
and characterized to potential gastroretentive effect, and 
possible use for gastric disease treatment, such as H. 
pylori infections. Floating microparticles composed by 
chitosan and one hydrophilic (HPMC) or one hydrophobic 
(EC) polymer were developed. Physicochemical 
characterization has shown the drug encapsulation and 
did not indicate chemical linkage occurrence between 
components. The microparticles floating ability study 
revealed no difference among the HPMC:CS samples, 
while microparticles containing a higher amount of 
EC presented poor flotation. The drug release study 
demonstrated better control of the MT release by EC:CS 
1:3 sample, and similar profiles among HPMC:CS 
samples. However, the microparticles composed by 
HPMC and CS presented the best relationship between 
floating ability and controlled drug release and it is 
believed to be ideal for floating gastroretentive systems 
regarding safe administration.
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